This question is particularly relevant with the passage of the Inflation Reduction Act (IRA) and the requirement that CMS negotiate a ‘maximum fair price’ for drugs with the greatest impact on Medicare outcomes. TO Vanguard in Health Affairs paper for Lin et al. (2023) compares how drug price negotiations differ between Canada, France, Germany, and the United States. Below is a helpful table, but read the full article. here.